Table 4.
The incidence of all-cause end-point events between the two groups.
| End-point events | Acarbose therapy free | Acarbose therapy | Statistical quantity | P |
|---|---|---|---|---|
| (n = 336) | (n = 1461) | |||
| All-cause death | ||||
| No, n (%) | 297 (88.39) | 1371 (93.84) | 12.16 (χ2) | < 0.001 |
| Yes, n (%) | 39 (11.61) | 90 (6.16) | ||
| Cardiac and cerebral vascular disease | ||||
| No, n (%) | 287 (85.42) | 1262 (86.38) | 0.21 (χ2) | 0.645 |
| Yes, n (%) | 49 (14.58) | 199 (13.62) | ||
| Cardiovascular disease | ||||
| No, n (%) | 305 (90.77) | 1343 (91.92) | 0.47 (χ2) | 0.491 |
| Yes, n (%) | 31 (9.23) | 118 (8.08) | ||
| Myocardial infarction | ||||
| No, n (%) | 324 (96.43) | 1435 (98.22) | 4.24 (χ2) | 0.040 |
| Yes, n (%) | 12 (3.57) | 26 (1.78) | ||
| Cerebrovascular disease | ||||
| No, n (%) | 318 (94.64) | 1380 (94.46) | 0.02 (χ2) | 0.892 |
| Yes, n (%) | 18 (5.36) | 81 (5.54) | ||
| Malignant tumor | ||||
| No, n (%) | 319 (94.94) | 1409 (96.44) | 1.67 (χ2) | 0.197 |
| Yes, n (%) | 17 (5.06) | 52 (3.56) | ||